Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef, Martin Nováček, Ülo Kivistik, Álvaro Réa-Neto, Nobuaki Shime, Ignacio Martin-Loeches, Jean François Timsit, Richard G. Wunderink, Christopher J. Bruno, Jennifer A. Huntington, Gina Lin, Brian Yu, Joan R. Butterton, Elizabeth G. Rhee
Dive into the research topics of 'Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial'. Together they form a unique fingerprint.